Inventiva (NASDAQ:IVA - Get Free Report) had its price target cut by investment analysts at Guggenheim from $12.00 to $9.00 in a report issued on Friday,Benzinga reports. The firm presently has a "buy" rating on the stock. Guggenheim's price target indicates a potential upside of 189.39% from the stock's current price.
Several other brokerages have also recently commented on IVA. TD Cowen initiated coverage on shares of Inventiva in a research report on Friday, February 21st. They issued a "buy" rating and a $10.00 price target for the company. HC Wainwright reiterated a "buy" rating and issued a $13.00 price objective on shares of Inventiva in a research note on Friday, March 28th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, Inventiva presently has an average rating of "Moderate Buy" and a consensus price target of $10.40.
Get Our Latest Report on IVA
Inventiva Stock Up 2.3 %
NASDAQ IVA traded up $0.07 on Friday, reaching $3.11. The stock had a trading volume of 7,472 shares, compared to its average volume of 62,291. The stock has a fifty day moving average price of $2.82 and a two-hundred day moving average price of $2.53. Inventiva has a 12-month low of $1.53 and a 12-month high of $3.98.
About Inventiva
(
Get Free Report)
Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.
Featured Articles
Before you consider Inventiva, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inventiva wasn't on the list.
While Inventiva currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
